Editorial

Inclusion of Racial and Ethnic Minorities in Cancer Clinical Trials: 30 Years After the NIH Revitalization Act, Where Are We?

Faith Mutale, DNP, CRNP

From Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia

Correspondence to: Faith Mutale, DNP, CRNP, Perelman Center for Advanced Medicine, 3400 Civic Center Boulevard, Philadelphia, PA 19104. E-mail: faith.mutale@pennmedicine.upenn.edu


J Adv Pract Oncol 2022;13(8):755–757 | https://doi.org/10.6004/jadpro.2022.13.8.2 | © 2022 Harborside™


  

ABSTRACT

The lack of diversity in cancer trials is a multifaceted, decades-old problem that has remained persistent despite efforts to increase the number of participants from underrepresented racial and ethnic backgrounds. This lack of meaningful improvement is a problem that continues to perpetuate inequities in cancer care. For optimal generalizability of clinical trial results, populations that are likely to be treated must be adequately represented. Beyond consensus statements, policy enactments, and federal mandates, strategic collaboration with at-risk underrepresented communities is critically necessary to improve the accrual of minorities to cancer clinical trials. As such, the clarion call is for advanced practitioners in oncology to take a keen interest in this issue and seek to develop population-specific strategies to bridge and eliminate the disparity gap and improve outcomes in these groups.




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.